Clinical trials: Neoplasm, Experimental
Non-Metastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8
An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer
This trial studies 7 Tesla magnetic resonance imaging (MRI) in diagnosing cognitive impairment in patients with prostate cancer that has not spread to other places in the body (non-metastatic) and who have or have not received…
- Conditions
- Non-Metastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- NCT04318028
- Testing
- 7 Tesla Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Southern California
Dementia, Mild
Investigational Dementia Treatment Study
This research investigates the effect of active versus sham tACS paired with cognitive exercises in a regimen protocol of weeks, everyday.
- Trial name
- tACS (NCT05203523)
- Testing
- transcranial alternative current stimulation (tACS), cognitive exercises
- Where
- 2 sites in Canada
- Volunteers
- 73 people
- Sponsor
- University of Manitoba
Prostate Cancer
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.
- Trial name
- CheckMate 9KD (NCT03338790)
- Testing
- nivolumab, docetaxel, enzalutamide
- Where
- 66 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- Bristol-Myers Squibb
Unresectable Melanoma, Metastatic Melanoma
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
This study will investigate the safety and activity of NEO-PTC-01 in patients with unresectable or metastatic melanoma. NEO-PTC-01 is an autologous personalized T cell (PTC) product for adoptive cell therapy that is manufactured…
- Trial name
- NCT04625205
- Testing
- NEO-PTC-01, IL-2, PD-1 Inhibitors
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 22 people
- Sponsor
- BioNTech US Inc.
Head and Neck Cancer
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
This is a study of Nivolumab in combination with experimental medication BMS-986205 compared to the standard of care EXTREME regimen in head and neck cancer that has come back after initial treatment, or is widespread when first…
- Trial name
- NCT03386838
- Testing
- Nivolumab, BMS-986205, Cetuximab
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors
A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn
This study is the first time BNT3210 will be tested in people. It will evaluate different dose levels to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.
- Trial name
- NCT07886684
- Testing
- BNT3210
- Volunteers
- 173 people
- Sponsor
- BioNTech SE
Chronic Disease, Cardiovascular Diseases
CEPPPIA Pilot. Experimental Center of Participative and Individualized Predictive Prevention in Auvergne
The state of health in France appears to be good with regard to major indicators such as life expectancy at birth. However, France is characterized by a high standardized rate of premature mortality (deaths occurring before the…
- Conditions
- Chronic Disease, Cardiovascular Diseases, Cancers, Diabetes Mellitus
- Trial name
- CEPPPIA (NCT03378895)
- Testing
- online questionnaire
- Where
- France
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
The aim of the REFRACT clinical trial is to find new therapies with improved outcomes compared to the current standard treatment available, in patients with relapsed or refractory follicular lymphoma.
- Trial name
- REFRACT (NCT05848765)
- Testing
- Epcoritamab, Lenalidomide, Rituximab
- Where
- 25 sites in United Kingdom
- Volunteers
- 284 people
- Sponsor
- University of Birmingham
Advanced Non-small Cell Lung Cancer (NSCLC)
Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer
This is a Phase 2 and open-label (subject will know the treatment he or she is receiving) study. The subject will receive either Erlotinib alone or Erlotinib + CS-7017 in this study.
- Trial name
- NCT01101334
- Testing
- CS-7017, erlotinib
- Where
- 17 sites in United States, Germany and 2 more
- Volunteers
- 90 people
- Sponsor
- Daiichi Sankyo
Advanced Cancers
Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial, An Umbrella Protocol
Primary Objective The primary objective of this study is to establish a program for the molecular profiling of patients with advanced cancer, with the goals of (1) providing a comprehensive characterization of the molecular…
- Trial name
- NCT00851032
- Testing
- Molecular Profiling Analyses
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or…
- Trial name
- NCT06121843
- Testing
- BMS-986393, Alnuctamab, Mezigdomide
- Where
- 19 sites in United States, Canada
- Volunteers
- 187 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Bereavement
Family Cancer Caregivers Receiving a Specific Supportive Care Intervention Pre- and Postloss
Background and study aims The effect of cancer caregiving may have profound impact on the psychosocial health of family caregivers and become evident after loss.
- Trial name
- FAM-SOTC-PL (NCT03850132)
- Testing
- FAM-SOTC-PL
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of Iceland
Cancer, Solid Tumor
MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer
The purpose of this Expanded Access Program (EAP) is to allow use of the investigational imaging agent, MNPR-101-DFO*-89Zr, with positron emission tomography/computed tomography (PET/CT) imaging, to non-invasively detect the…
- Conditions
- Cancer, Solid Tumor, Solid Tumor, Adult
- Trial name
- NCT06980506
- Testing
- MNPR-101-DFO*-89Zr
- Where
- United States
- Sponsor
- Monopar Therapeutics
Hepatoma, Liver Neoplasms
Sorafenib and TRC105 in Hepatocellular Cancer
Background: Sorafenib is a drug that has been approved to treat kidney and liver cancer (hepatocellular carcinoma, or HCC) and has been shown to prolong survival in patients with HCC.
- Conditions
- Hepatoma, Liver Neoplasms, Adenoma, Liver Cell, Carcinoma, Hepatocellular
- Trial name
- NCT01306058
- Testing
- TRC 105, Sorafenib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Malaria
Malaria Vaccine in Children in Mali
This study will test an experimental vaccine called AMA1-C1 in children to see if it is safe and if it reduces episodes of malaria parasitemia (parasites in the blood) in children exposed to malaria.
- Trial name
- NCT00341250
- Testing
- AMA1-C1/Alhydrogel Malaria Vaccine
- Where
- 2 sites in Mali
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Solid Tumor, Lymphoma
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in…
- Trial name
- NCT03013491
- Testing
- CX-072, ipilimumab, vemurafenib
- Where
- 31 sites in United States, Netherlands and 4 more
- Volunteers
- 196 people
- Sponsor
- CytomX Therapeutics
Localized Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
This phase II trial tests whether 68Ga-FAPI-46 positron emission tomography (PET)/computed tomography (CT) scan works to image cancer-associated fibroblasts (CAFs) in patients with pancreatic ductal adenocarcinoma (PDA) that has…
- Conditions
- Localized Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8
- Trial name
- NCT05518903
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Mayo Clinic
Breast Neoplasm
Feasibility of Preoperative Tattooing of Percutaneously Biopsied Axillary Lymph Node: A Quasi Experimental Pilot Study
This study evaluates utility of a novel technique using India Ink to aid in the identification and retrieval of axillary lymph nodes during surgery, in breast cancer patients with suspicious lymph nodes.
- Trial name
- NCT03939598
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Aga Khan University
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
This phase Ib/II trial compares the effect of teclistamab and pomalidomide to standard treatment with carfilzomib, pomalidomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of…
- Trial name
- NCT07463807
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasm
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
An open-label, Phase I, dose escalation study of CS-7017 administered by mouth in sequential cohorts of 3 to 6 participants with advanced or metastatic malignancies.
- Trial name
- NCT00408434
- Testing
- CS-7017
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo